Physician profile
Hayan Dayoub
NPI 1740322544
$2,374.96
in general payments reported to CMS, 2019-2025
14 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $81.98 · 2021: $123 · 2022: $152 · 2023: $32.69 · 2024: $361 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $700.19 | 2019 | |
| Penumbra, INC. | $533.18 | 2019-2022 | |
| Microvention, INC. | $335.74 | 2019-2024 | Sofia 6f-131cm Str, Stent |
| Livanova USA, INC. | $196.48 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Depuy Synthes Sales INC. | $115.61 | 2019-2020 | |
| Choice Spine, LLC | $94.83 | 2019 | |
| Stryker Corporation | $88.93 | 2019-2022 | |
| Integra Lifesciences Corporation | $79.16 | 2023-2024 | Duraseal Exact Spinal Sealant System, Codman Certas, Cusa Clarity |
| Imperative Care, INC | $67.06 | 2021-2022 | |
| Medtronic USA, INC. | $63.02 | 2019 | |
| Genzyme Corporation | $59.66 | 2025 | |
| Neurocrine Biosciences, INC. | $22.75 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.35 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayan Dayoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.